GE HealthCare Technologies Cash, cash equivalents, and restricted cash decreased by 49.4% to $2.29B in Q1 2026 compared to the prior quarter. Year-over-year, this metric declined by 7.6%, from $2.47B to $2.29B. Over 3 years (FY 2022 to FY 2025), Cash, cash equivalents, and restricted cash shows an upward trend with a 46.2% CAGR. This decline may warrant attention — for this metric, higher values are generally preferred.
An increase suggests improved liquidity and financial flexibility, while a decrease may indicate cash burn or significant capital deployment.
This represents the total liquid assets held by the company, including cash on hand, bank deposits, and short-term highl...
Standard across all public companies; peers in medical technology typically maintain sufficient cash to fund R&D and M&A.
other_cash_cash_equivalents_restricted_cash_and_restrict_8382e2| Q4 '22 | Q1 '23 | Q2 '23 | Q3 '23 | Q4 '23 | Q1 '24 | Q2 '24 | Q3 '24 | Q4 '24 | Q1 '25 | Q2 '25 | Q3 '25 | Q4 '25 | Q1 '26 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Value | $1.45B | $2.33B | $1.94B | $2.42B | $2.50B | $2.56B | $2.02B | $3.57B | $2.89B | $2.47B | $3.76B | $4.03B | $4.51B | $2.29B |
| QoQ Change | — | +61.0% | -16.7% | +24.7% | +3.6% | +2.4% | -21.4% | +77.1% | -19.0% | -14.4% | +52.2% | +7.0% | +12.0% | -49.4% |
| YoY Change | — | — | — | — | +73.3% | +10.1% | +3.9% | +47.6% | +15.4% | -3.5% | +86.7% | +12.9% | +56.2% | -7.6% |